Medical Condition

The identification of NMDAR encephalitis has significantly shifted paradigms in neuropsychiatry and neurology, illustrating that autoimmune encephalitides may underlie a subset of psychiatric and cognitive syndromes previously considered idiopathic. Awareness of its infectious associations has broadened understanding of post-infectious autoimmunity and highlighted the need for vigilance following viral encephalitis. NMDAR encephalitis serves as a model disease for the study of neuroinflammation, autoantibody-driven pathophysiology, and the interface between the immune system and mental health.

NMDAR encephalitis is a severe autoimmune neuropsychiatric disorder characterized by the production of autoantibodies against the NR1 subunit of the N-methyl-D-aspartate receptor. It typically presents with a multistage clinical course. Initial symptoms often include psychiatric manifestations such as anxiety, agitation, hallucinations, delusions, and behavioral changes. These may progress to include seizures, movement disorders (e.g., orofacial dyskinesias), decreased level of consciousness, autonomic instability, and central hypoventilation. The disease can mimic primary psychiatric disorders in its early stages, particularly in adolescents and young adults.

NMDAR encephalitis is among the most common forms of autoimmune encephalitis, with higher prevalence in females, especially those between the ages of 12 and 45. The disease can also affect children and older adults, though with differing clinical profiles. Genetic predisposition remains under investigation, but associations with specific HLA class II alleles (e.g., HLA-DRB1*16:02) have been reported, suggesting an immunogenetic susceptibility, though further validation is needed. The presence of ovarian teratomas expressing NMDARs is a notable risk factor in female patients. These tumors may serve as peripheral antigen sources that initiate central immune activation.

The neuropsychiatric presentation is often abrupt and includes anxiety, mood lability, paranoia, hallucinations, delusions, agitation, and disorganized thought processes. As the disease progresses, patients may develop catatonia, seizures, movement disorders, autonomic instability, and hypoventilation. Though not classically described as a core feature, OCD-like symptoms may arise in NMDAR encephalitis, likely reflecting immune-mediated disruption of cortico-striato-thalamo-cortical (CSTC) circuits and altered glutamatergic tone. Cognitive decline is typically diffuse, affecting attention, working memory, and executive function.

Low-titer IgM and IgA NMDAR antibodies may be detected in unrelated conditions or even in healthy individuals and are not considered pathogenic. By contrast, the production of IgG1 autoantibodies directed against extracellular epitopes of the NR1 subunit defines NMDAR encephalitis. Unlike most other post-infectious neuropsychiatric disorders, detection of these IgG1 autoantibodies in the cerebral spinal fluid establishes a clear diagnosis.

Treatment of NMDAR encephalitis focuses on immunotherapy and removal of associated tumors, particularly teratomas, when present. First-line therapies typically include corticosteroids, intravenous immunoglobulin, or plasma exchange. In cases refractory to initial treatment, second-line immunosuppressants such as anti-CD20 monoclonal antibodies (e.g., rituximab) or alkylating agents are employed. Long-term immunosuppression may be required in relapsing or persistent cases. Antiseizure medications and psychiatric support may be needed for symptomatic management, though these do not address the underlying autoimmune process. Early intervention is associated with improved prognosis and reduced neurological sequelae.

Although the exact mechanism by which antibodies access the central nervous system remains unclear, it is hypothesized that blood-brain barrier disruption (such as from prior viral encephalitis or systemic inflammation) permits their entry. Once within the CNS, these antibodies bind to neuronal receptors without triggering direct cytotoxicity. The resulting receptor internalization and downregulation impair glutamatergic neurotransmission and contribute to the diverse neuropsychiatric symptoms observed. Inflammatory cytokines and activated microglia further amplify this process, sustaining synaptic dysfunction and neural network disorganization.

NMDAR encephalitis exemplifies a neuroimmune disorder in which infection, autoimmunity, and neuroinflammation converge to produce complex neuropsychiatric symptoms. Its early psychiatric presentation often challenges clinicians, but recognition of the autoimmune etiology is essential for timely treatment. The dynamic interplay between neuronal autoantibodies and neuroinflammatory pathways underlies both acute symptoms and long-term outcomes. Advances in understanding its mechanisms continue to shape more targeted therapeutic approaches.

Prüss, H. (2021). Autoantibodies in neurological disease. Nature Reviews Immunology, 21(12), 798–811. https://doi.org/10.1038/s41577-021-00633-8

Leypoldt, F., Armangue, T., Dalmau, J., & Graus, F. (2015). Herpes simplex virus–induced anti-NMDA receptor encephalitis: A case of molecular mimicry? Neurology: Neuroimmunology & Neuroinflammation, 2(3), e113. https://doi.org/10.1212/NXI.0000000000000113

Armangue, T., Leypoldt, F., & Dalmau, J. (2013). Autoimmune encephalitis in children. Journal of Child Neurology, 28(3), 307–322. https://doi.org/10.1177/0883073812473510

Lancaster, E., & Dalmau, J. (2012). Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nature Reviews Neurology, 8(7), 380–390. https://doi.org/10.1038/nrneurol.2012.110

Dalmau, J., Tüzün, E., Wu, H. Y., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J., Shimazaki, H., Koide, R., King, D., … Lynch, D. R. (2007). Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. The Lancet Neurology, 6(12), 1091–1098. https://doi.org/10.1016/S1474-4422(07)70324-3